Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShort-Term Debt repayments
Ratios

Gain Therapeutics (GANX) Short-Term Debt repayments (2022 - 2025)

Gain Therapeutics (GANX) has 4 years of Short-Term Debt repayments data on record, last reported at $24996.0 in Q3 2025.

  • For Q3 2025, Short-Term Debt repayments rose 8.13% year-over-year to $24996.0; the TTM value through Sep 2025 reached $94256.0, up 3.95%, while the annual FY2024 figure was $90879.0, 2.03% up from the prior year.
  • Short-Term Debt repayments reached $24996.0 in Q3 2025 per GANX's latest filing, up from $24238.0 in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $37974.0 in Q1 2022 and bottomed at -$1363.0 in Q2 2022.
  • Average Short-Term Debt repayments over 4 years is $22013.1, with a median of $22579.0 recorded in 2023.
  • The widest YoY moves for Short-Term Debt repayments: up 1732.13% in 2023, down 43.09% in 2023.
  • A 4-year view of Short-Term Debt repayments shows it stood at $21582.0 in 2022, then grew by 4.62% to $22579.0 in 2023, then increased by 0.89% to $22780.0 in 2024, then increased by 9.73% to $24996.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Short-Term Debt repayments were $24996.0 in Q3 2025, $24238.0 in Q2 2025, and $22242.0 in Q1 2025.